Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Orthopaedics and Related Research®
Published in: Clinical Orthopaedics and Related Research® 11/2017

01-11-2017 | CORR Insights

CORR Insights®: What Should Define Preoperative Anemia in Primary THA?

Author: Matthew P. Abdel, MD

Published in: Clinical Orthopaedics and Related Research® | Issue 11/2017

Login to get access

Excerpt

Blood conservation is an essential aspect of THA. Transfusions have risks, including the transmission of blood-borne infections, transfusion-related reactions, transfusion-related acute lung injury, circulatory overload, immune-mediated transfusion effects, and periprosthetic joint infections [1]. The routine use of tranexamic acid (TXA) has become common at most institutions since it is safe, inexpensive, easy to administer, and effective at minimizing perioperative blood transfusion [3‐6, 8, 9]. Intravenous (IV) TXA can be given in several different ways. The Mayo Clinic protocol calls for administering TXA once prior to incision (1 g intravenous in 50 mL of normal saline) and once during wound closure [4]. In light of TXA’s widespread use, historical hemoglobin (Hgb) cutoffs to predict the risk of a postoperative blood transfusion are dated, and contemporary data are required. …
Literature
1.
Abdel MP, Morrey BF. Implications of revision total elbow arthroplasty on blood transfusion. J Shoulder Elbow Surg. 2010;19:190–195.CrossRefPubMed
2.
Amundson AW, Johnson RL, Abdel MP, Mantilla CB, Panchamia JK, Taunton MJ, Kralovec ME, Hebl JR, Schroeder DR, Pagnano MW, Kopp SL. A Three-arm randomized clinical trial comparing continuous femoral plus single-injection sciatic peripheral nerve blocks versus periarticular injection with ropivacaine or liposomal bupivacaine for patients undergoing total knee arthroplasty. Anesthesiology. 2017;126:1139–1150.CrossRefPubMed
3.
Duncan CM, Gillette BP, Jacob AK, Sierra RJ, Sanchez-Sotelo J, Smith HM. Venous thromboembolism and mortality associated with tranexamic acid use during total hip and knee arthroplasty. J Arthroplasty. 2015;30:272–276.CrossRefPubMed
4.
Gillette BP, DeSimone LJ, Trousdale RT, Pagnano MW, Sierra RJ. Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty. Clin Orthop Relat Res. 2013;471:150–154.CrossRefPubMed
5.
Gillette BP, Maradit Kremers H, Duncan CM, Smith HM, Trousdale RT, Pagnano MW, Sierra RJ. Economic impact of tranexamic acid in healthy patients undergoing primary total hip and knee arthroplasty. J Arthroplasty. 2013;28:137–139.CrossRefPubMed
6.
Sabbag OD, Abdel MP, Amundson AW, Larson DR, Pagnano MW. Tranexamic acid was safe in arthroplasty patients with a history of venous thromboembolism: A matched outcome study. J Arthroplasty. [Published online ahead of print February 14, 2017]. DOI: 10.​1016/​j.​arth.​2017.​02.​008
7.
Sculco PK, Pagnano MW. Perioperative solutions for rapid recovery joint arthroplasty: Get ahead and stay ahead. J Arthroplasty. 2015;30:518–520.CrossRefPubMed
8.
Whiting DR, Duncan CM, Sierra RJ, Smith HM. Tranexamic acid benefits total joint arthroplasty patients regardless of preoperative hemoglobin value. J Arthroplasty. 2015;30:2098–2101.CrossRefPubMed
9.
Whiting DR, Gillette BP, Duncan C, Smith H, Pagnano MW, Sierra RJ. Preliminary results suggest tranexamic acid is safe and effective in arthroplasty patients with severe comorbidities. Clin Orthop Relat Res. 2014;472:66–72.CrossRefPubMed
Metadata
Title
CORR Insights®: What Should Define Preoperative Anemia in Primary THA?
Author
Matthew P. Abdel, MD
Publication date
01-11-2017
Publisher
Springer US
Published in
Clinical Orthopaedics and Related Research® / Issue 11/2017
Print ISSN: 0009-921X
Electronic ISSN: 1528-1132
DOI
https://doi.org/10.1007/s11999-017-5485-4

Other articles of this Issue 11/2017

Clinical Orthopaedics and Related Research® 11/2017 Go to the issue

CORR Insights

CORR Insights®: PROMIS Pain Interference and Physical Function Scores Correlate With the Foot and Ankle Ability Measure (FAAM) in Patients With Hallux Valgus

CORR Insights

CORR Insights®: How Long Does Antimycobacterial Antibiotic-loaded Bone Cement Have In Vitro Activity for Musculoskeletal Tuberculosis?

Classifications in Brief

Classifications in Brief: Hamada Classification of Massive Rotator Cuff Tears

Medicolegal Sidebar

Medicolegal Sidebar: (Mis)Informed Consent in Medical Negligence Lawsuits

Reply to the Letter to the Editor

Reply to the Letter to the Editor: Not the Last Word: Rethinking the Resident Research Requirement

Clinical Research

What Are the Complications, Survival, and Outcomes After Revision to Reverse Shoulder Arthroplasty in Patients Older Than 80 Years?